Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: A phase II trial

Journal of Clinical Oncology

Volumn 22, Issue 3, 2004, Pages 424-431

  Marchetti, Monia ^b   Barosi, Giovanni ^a   Balestri, Francesca ^b   Viarengo, Gianluca ^b   Gentili, Sara ^b   Barulli, Sara ^b   Demory, Jean Loup ^b   Ilariucci, Fiorella ^b   Volpe, Antonio ^b   Bordessoule, Dominique ^b   Grossi, Alberto ^b   Le Bousse Kerdiles, Marie Caroline ^b   Caenazzo, Andrea ^b   Pecci, Alessandro ^b   Falcone, Antonietta ^b   Broccia, Giorgio ^b   Bendotti, Cesarina ^b   Bauduer, Fredric ^b   Buccisano, Francesco ^b   Dupriez, Brigitte ^b  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

THALIDOMIDE; IMMUNOSUPPRESSIVE AGENT;

ANEMIA; ARTICLE; CLINICAL TRIAL; CYTOPENIA; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; MYELOFIBROSIS; MYELOID METAPLASIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SPLENOMEGALY; THROMBOCYTE COUNT; THROMBOCYTOSIS; ADOLESCENT; ADULT; AGED; HOSPITALIZATION; LEUKOPENIA; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; SAFETY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKOPENIA; MALE; MIDDLE AGED; MYELOFIBROSIS; MYELOID METAPLASIA; PLATELET COUNT; SAFETY; SEVERITY OF ILLNESS INDEX; SPLENOMEGALY; THALIDOMIDE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 1442290394     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.08.160     Document Type: Article

References (24)

1. Barosi G: Myelofibrosis with myeloid metaplasia: Diagnostic definition and prognostic classification for clinical studies and treatment guidelines. J Clin Oncol 17:2954-2970, 1999
2. Tefferi A: Myelofibrosis with myeloid metaplasia. N Engl J Med 342:1255-1265, 2000
3. Guardiola P, Anderson JE, Bandini G, et al: Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: A European Group for Blood and Marrow Transplantation, Societe Francaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood 93:2831-2838, 1999
4. Dupriez B, Morel P, Demory JL, et al: Prognostic factors in agnogenic myeloid metaplasia: A report on 195 cases with a new scoring system: Blood 88:1013-1018, 1996
5. Visani G, Finelli C, Castelli U, et al: Myelofibrosis with myeloid metaplasia: Clinical and haematological parameters predicting survival in a series of 133 patients. Br J Haematol 75:4-9, 1990
6. Barosi G, Elliott M, Canepa L, et al: Thalidomide in myelofibrosis with myeloid metaplasia: A pooled-analysis of individual patient data from 5 studies: Leuk Lymphoma 43:2301-2307, 2002
7. Canepa L, Ballerini F, Varaldo R, et al: Thalidomide in agnogenic and secondary myelofibrosis. Br J Haematol 115:313-315, 2001
8. Elliott MA, Mesa RA, Li CY, et al: Thalidomide treatment in myelofibrosis with myeloid metaplasia. Br J Haematol 117:288-296, 2002
9. Di Raimondo F, Azzaro MP, Palumbo GA, et al: Elevated vascular endothelial growth factor (VEGF) serum levels in idiopathic myelofibrosis. Leukemia 15:976-980, 2001
10. Piccaluga PP, Visani G, Pileri SA, et al: Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study. Leukemia 16:1609-1614, 2002
11. Merup M, Kutti J, Birgergard G, et al: Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia. Med Oncol 19:79-86, 2002
12. Barosi G, Grossi A, Comotti B, et al: Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 114:78-83, 2001
13. Mesa RA, Steensma DP, Pardanani A, et al: A phase II trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 101:2534-2541, 2003
14. Neben K, Moehler T, Benner A, et al: Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clin Cancer Res 8:3377-3382, 2002
15. Barosi G, Ambrosetti A, Finelli C, et al: The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia. Br J Haematol 104:730-737, 1999
16. Johns MW: A new method for measuring daytime sleepiness: The Epworth sleepiness scale: Sleep 14:540-545, 1991
17. Vignatelli L, Plazzi G, Barbato A, et al: Italian version of the Epworth sleepiness scale: External validity. Neurol Sci 23:295-300, 2003
18. Calhoun E, Fishman DA, Roland PY, et al: Validity and selective sensitivity of the FACT/GOG-Ntx. Proc Am Soc Clin Oncol 2000 (abstr)
19. Yellen SB, Cella DF, Webster K, et al: Measuring fatigue and other anemia-related symptoms with the Functional Assessment Cancer Therapy (FACT) measurement system. J Pain Symptom Manage 13:63-74, 1997
20. Cella D, Eton DT, Lai JS, et al: Combining anchor and distribution-based methods to derive minimally clinically important differences on the functional assessment of cancer therapy (FACT) Anemia and Fatigue subscales. J Pain Symptom Manage 24:548-561, 2002
21. Raza A, Meyer P, Dutt D, et al: Thalidomide produces transfusion independence in long-standing refractory anemia of patients with myelodysplastic syndromes. Blood 98:958-965, 2001
22. Bouroncle B, Doan C: Myelofibrosis: Clinical, hematological, and pathologic study of 110 patients. Am J Med Sci 243:697-715, 1962
23. Centenara E, Guarnone R, Ippoliti G, et al: Cyclosporin-A in severe refractory anemia of myelofibrosis with myeloid metaplasia: A preliminary report. Haematologica 83:622-626, 1998
24. Cella D, Laj JS, Chang CH, et al: Fatigue in cancer patients compared with fatigue in the general United States population. Cancer 94: 528-538, 2002